Afficher la couverture 'Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers | ter Brugge, Petra' en grand format
/5

0 avis

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

Archive ouverte

ter Brugge, Petra | Moser, Sarah | Bièche, Ivan | Kristel, Petra | Ibadioune, Sabrina | Eeckhoutte, Alexandre | de Bruijn, Roebi | van der Burg, Eline | Lutz, Catrin | Annunziato, Stefano | de Ruiter, Julian | Masliah Planchon, Julien | Vacher, Sophie | Courtois, Laura | El-Botty, Rania | Dahmani, Ahmed | Montaudon, Elodie | Morisset, Ludivine | Sourd, Laura | Huguet, Léa | Derrien, Heloise | Nemati, Fariba | Chateau-Joubert, Sophie | Larcher, Thibaut | Salomon, Anne | Decaudin, Didier | Reyal, Fabien | Coussy, Florence | Popova, Tatiana | Wesseling, Jelle | Stern, Marc-Henri | Jonkers, Jos | Marangoni, Elisabetta

Edité par CCSD ; Nature Publishing Group -

International audience. The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial and there is a medical need for predictive biomarkers. We assess the in vivo response to platinum agents in 55 patient-derived xenografts (PDX) of TNBC to identify determinants of response. The HRD status, determined from whole genome sequencing, is highly predictive of platinum response. BRCA1 promoter methylation is not associated with response, in part due to residual BRCA1 gene expression and homologous recombination proficiency in different tumours showing mono-allelic methylation. Finally, in 2 cisplatin sensitive tumours we identify mutations in XRCC3 and ORC1 genes that are functionally validated in vitro. In conclusion, our results demonstrate that the genomic HRD is predictive of platinum response in a large cohort of TNBC PDX and identify alterations in XRCC3 and ORC1 genes driving cisplatin response.

Suggestions

Du même auteur

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Archive ouverte | Coussy, Florence | CCSD

Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand breaks (DSBs) during replication, which are repaired by homologous recombination (HR). Triple-negative breast cancer (TNBC) could be eli...

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

Archive ouverte | Montaudon, Elodie | CCSD

International audience. A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we per...

Capecitabine efficacy is correlated with TYMP and RB1 expression in PDX established from triple-negative breast cancers

Archive ouverte | Marangoni, Elisabetta | CCSD

International audience. Purpose: Triple-negative breast cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy have a poor outcome. We developed patient-derived xenografts (PDX) from residual tu...

Chargement des enrichissements...